Hemophilia Treatment Market

Global Hemophilia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028: Increasing prevalence of hemophilia, rising advancements in the healthcare industry, and growing government initiatives to promote awareness about hemophilia treatment are some of the major factors driving the growth of the Market. 

The Global Hemophilia Treatment Market is valued at USD 11.07 Billion in 2021 and is expected to reach USD 16.44 Billion by 2028 with a CAGR of 5.8% over the forecast period.  

Scope- 

Hemophilia is a rare disorder in which the patient's blood does not clot normally because it does not have enough blood-clotting proteins (clotting factors). If patients have hemophilia, they may bleed longer after an injury than if the patient had normal blood clots. Several types of clotting elements are associated with different types of hemophilia. The main treatment for serious hemophilia is to replace the specific clotting factor patients need through a tube placed in a vein. Hemophilia treatment involves administering drugs intravenously or intranasally to prevent frequent internal bleeding that can lead to arthritis or joint destruction or infection. It is an inherited bleeding disorder that can cause persistent bleeding or discharge after injury or surgery. In severe cases, prolonged bleeding occurs after minor trauma or even in the absence of injury. 

The COVID-19 pandemic has shown a positive impact on the growth of the global hemophilia treatment market. People who have been diagnosed with hemophilia are more likely to develop infectious diseases. Even in the pre-COVID era, blood-borne viruses have seriously targeted hemophilia patients. Hemophilia patients are advised to monitor their blood pressure and follow medical guidelines to ensure the good condition of their immune systems. Hence, the epidemic has increased the market value of hemophilia treatment. 

The global hemophilia treatment market is segmented on the disease type, product type, route of administration, therapy, end-user, region & country level. Based on disease type, the market is segmented into von Willebrand disease, hemophilia A, hemophilia B, and others. By product type, the market is segmented into plasma-derived factor concentrate, desmopressin, antifibrinolytics, recombinant factor concentrates, and others. By route of administration, the market is segmented into a nasal spray, and injectable. By therapy, the global hemophilia treatment market is segmented into replacement therapy, immune tolerance induction therapy, gene therapy, and others. By end user, the global hemophilia treatment market is segmented into online, hospital pharmacy, retail pharmacy, and others. 

The regions covered in the global hemophilia treatment market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global hemophilia treatment is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc. 

Key Players- 

Some major key players for the global hemophilia treatment market report cover prominent players like

• Grifols SA
• CSL Ltd.
• Octapharma AG
• Novo Nordisk
• Kedrion
• Pfizer  
• Bayer AG
• Biogen Idec  
• Hospira  
• Baxter International  
• and others.

Segmentation- 

By Disease Type: 

• Von Willebrand Disease 
• Hemophilia A 
• Hemophilia B 
• Others 

By Product Type: 

• Plasma-derived Factor Concentrate 
• Desmopressin 
• Antifibrinolytics 
• Recombinant Factor Concentrate 
• Others 

By Route of Administration: 

• Nasal Spray
• Injectable 

By Therapy: 

• Replacement Therapy 
• Immune Tolerance Induction Therapy 
• Gene Therapy 
• Others 

By End-User: 

• Online 
• Hospital Pharmacy 
• Retail Pharmacy 
• Others 

Increasing Prevalence of Hemophilia, Rising Advancements in Healthcare Industry, and Growing Government Initiatives to Promote Awareness About Hemophilia Treatment Are Some of The Major Factors Driving the Growth of The Global Hemophilia Treatment Market 

One of the major factors in the growth of the hemophilia treatment market is the increasing prevalence of hemophilia. The increasing prevalence of hemophilia, contributing to the growing demand for treatment options, is a major factor driving the expansion of the hemophilia treatment market. Severe patients require a regular hemophilia treatment regimen to maintain adequate clotting elements in the bloodstream to prevent bleeding. Furthermore, patients receiving appropriate care can be expected to develop fewer co-morbid conditions and have a reduced risk of serious bleeding. For instance, according to the Centres for Disease Control and Prevention, on August 8th, 2022, the estimated occurrence of hemophilia in the United States was 12 cases per 100,000 United States males for hemophilia A and 3.7 cases per 100,000 US males for hemophilia B. The estimated incidence of hemophilia in US births is 1 in every 5,617 male births for hemophilia A and 1 in every 19,283 male births for hemophilia B. Thus, the ever-increasing patient population has significantly increased the demand for hemophilia treatment, which will increase the product adoption rate. 

In addition, the rising advancements in the healthcare industry are boosting the growth of the hemophilia treatment market. On July 21, 2022, experts from University College London (UCL), the Royal Free Hospital in London, and the biotechnology company Freeline Therapeutics developed a gene therapy injection called FLT180a, which is useful for eliminating weekly injections in patients with clotting elements. In mid-2022, the European Medicines Agency (EMA) has recommended that Roctavian (valoctocogene roxaparvovec) be granted conditional marketing authorization for the treatment of serious hemophilia A in the European Union (EU). On September 22, 2022, Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderate to severe hemophilia A, has restarted enrollment. Trial sites will resume enrollment this month, with dosing expected to resume in October. All test sites are expected to be active by the end of 2022, and a significant reading is expected in the first half of 2024. On May 9, 2022, Precision Biologic launched a new product to improve testing for hemophilia B. on May 16th, 2022; Takeda Pharmaceutical Co Ltd announced the expansion of its rare disease’s portfolio in India with the launch of Adynovate, used in the treatment of hemophilia. Similarly, the market is getting a big boost due to the increasing government support as well as new technologies emerging from the hard work of health scientists. 

Moreover, the growing government initiatives to promote awareness about hemophilia treatment among the populace are also supplementing the hemophilia treatment market growth. For instance, according to National Blood Authority Australia, the NBA provides funding through AHCDO to hire data managers at each hemophilia treatment center and supports a group of AHCDO data managers to ensure coordination and consistency in data entry.

However, the high cost of recombinant products and the serious adverse effects associated with plasma-derived products associated with hemophilia treatment may hinder the growth of the global hemophilia treatment market. Despite that, the rising use of prophylactic treatment for hemophilia may create more opportunities in the global hemophilia treatment market. 

North America Holds a Major Share in the Global Hemophilia Treatment Market:  

Geographically, North America is holding a major share in the global hemophilia treatment market within the forecast period due to the increasing number of hemophilic patients, rising demand for prophylactic treatments, and growing medical research these factors boost the market. An increasing number of hemophilic patients is driving the growth of the hemophilia treatment market. According to the U.S. Centers for Disease Control, about 3 million people nationwide suffer from bleeding disorders. And also, according to ASH Clinical, on February 1st, 2020; Approximately 20,000 people in the US are living with the genetic bleeding disorder hemophilia, and more than 60% of those people have moderate or severe hemophilia that requires lifelong treatment with expensive medications and clotting factors. In addition, the rising demand for prophylactic treatments is another factor supplementing the market growth in this region. For instance, as per the news published, on January 31st, 2022; FDA approved prophylactic treatment with VONVENDI for adult patients living with severe type 3 von Willebrand disease (VWD). Due to the growing market benefits of all these factors, North America holds a major share in the global hemophilia treatment market. 

The Asia Pacific is the fastest-growing region in the global hemophilia treatment market due to increasing investments in research and development of new products for the treatment of hemophilia, the rising number of hemophilic patients, and technological advancements these factors boost the market. For instance, Hemophilia, a rare disease, has been a long-standing problem with a small but critical number of cases. In the Indian context, more than 1,36,000 people have been diagnosed (according to prevalence). The number is 1 in every 10,000 male births. Of the total number, 19,690 have been reported as Hem-A patients. At a time when the diagnosis rate of hemophilia is as low as 13 percent, spreading awareness about it has become imperative. And the government of India is currently working on it on a large scale. which will provide huge opportunities for the market in India as well in the coming time. In other countries in Asia Pacific, such government campaigns are also underway, which can greatly expand the market in Asia Pacific in the coming period. 

Recent Developments- 

The European Commission (EC) Granted Approval for BioMarin’s Gene Therapy to Treat Hemophilia A 

On August 25th, 2022- the European Commission (EC) granted a conditional marketing authorization (CMA) for BioMarin Pharmaceutical's gene therapy, Roctavian (valoctocogene roxaparvovec), to treat adults with severe hemophilia A (congenital factor VIII deficiency). Treatment is indicated for patients with no history of factor VIII inhibitors and no detectable antibodies to adeno-associated virus serotype 5 (AAV5). 

Takeda Launched Adynovate for Prophylaxis Treatment of Hemophiliac Patients in India. 

On May 17th, 2022- Takeda Pharmaceutical Company Limited launched an extended half-life recombinant factor VIII (rFVIII) treatment under the brand name Adynovate using an established technology (controlled PEGylation) for hemophilia A patients. Takeda is a global, values-based, R&D-driven biopharmaceutical leader with an innovative rare disease portfolio in India. 

FDA Approved Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors 

On April 1st, 2020- the US Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes in adults and adolescents 12 years of age or older with hemophilia A or B inhibitors (neutralizing antibodies). Seven facts contain an active ingredient expressed in genetically engineered rabbits.  

Report Analysis	Details
Historical data	2018 - 2021
Forecast Period	2022 - 2028
Market Size in 2021:	USD 11.07 Billion
Base year considered	2021
Forecast Period CAGR %:	5.8%
Market Size Expected in 2028:	USD 16.44 Billion
Tables, Charts & Figures:	175
Pages	200
Companies	Grifols SA, CSL Ltd., Octapharma AG, Novo Nordisk, Kedrion, Pfizer, Bayer AG, Biogen Idec, Hospira, Baxter International, and others
Segments Covered	By Disease Type, By Product Type, By Route of Administration, By Therapy, By End-User
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa